AI-Driven Pharmacovigilance: Advances in Adverse Drug Reaction Detection and Signal Management - A Review

Authors

  • Sumit Dilare Department of Pharmacology, Indore Mahavidyalaya, Indore, Madhya Pradesh
  • Raj Baghel Department of Pharmacology, Indore Mahavidyalaya, Indore, Madhya Pradesh
  • Anil Kumar Yadav Department of Pharmacology, Indore Mahavidyalaya, Indore, Madhya Pradesh
  • Muskan Tomar Department of Pharmacology, Indore Mahavidyalaya, Indore, Madhya Pradesh

DOI:

https://doi.org/10.22270/ajprd.v14i3.1797

Keywords:

, Sustained release, In vitro buoyancy, Floating drug delivery system, Bilayer tablet

Abstract

Pharmacovigilance plays a critical role in drug safety through its process of monitoring, detecting, and preventing adverse drug reactions (ADRs). Traditional pharmacovigilance methods depend on manual data processing together with spontaneous reporting systems which require extensive time for the execution of their work but lack operational efficiency. Artificial intelligence (AI) has developed into a revolutionary healthcare solution during the past several years because it provides organizations with powerful data processing and pattern discovery abilities. The study demonstrates how AI technology functions in pharmacovigilance through its two main functions of ADR detection and signal management. AI-based techniques use machine learning and natural language processing to process extensive data from multiple sources which include electronic health records and clinical databases and social media platforms. The current approaches enable organizations to identify drug safety signals at an early stage while achieving higher precision in their assessment process and conducting ongoing safety surveillance. AI helps organizations to verify their signals which enables them to establish signal importance and make decisions about regulatory matters. The use of AI in pharmacovigilance shows benefits but organizations need to deal with three major obstacles which include data quality issues and privacy risks and regulatory restrictions. The research demonstrates that AI-powered pharmacovigilance systems will enhance drug safety monitoring together with healthcare results while establishing more efficient and proactive pharmacovigilance systems for upcoming development.

 

Downloads

Download data is not yet available.

References

Algarvio RC, Conceição J, Rodrigues PP, Ribeiro I, Ferreira-da-Silva R. Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool. Int J Clin Pharm. 2025;47(4):932-944.

Shamim MA, Arora P, Dwivedi P. Artificial intelligence and big data for pharmacovigilance and patient safety. J Med Surg Public Health. 2024;3:100139.

Warner J, Jardim AP, Albera C. Artificial intelligence in pharmacovigilance signal management. Pharm Med. 2025;39(3):183-198.

Campbell JE, Gossell-Williams M, Lee MG. A review of pharmacovigilance. West Indian Med J. 2015;63(7):771-774.

Alshahrani S, Ali M, Alsreaya R, Najie M, Hijri A, Almalki A, et al. Pharmacovigilance in practice: knowledge, attitudes, and practices of pharmacists and pharmacy technicians in Saudi Arabia. J Res Pharm Pract. 2025;14(2):50-58.

Aizpurua-Arruti X, Goyenechea E, Isla A, Oñatibia-Astibia A, Malet-Larrea A, Gastelurrutia MA, et al. Impact of additional monitoring on pharmacovigilance and pharmacists' role: a scoping review. Pharmacoepidemiol Drug Saf. 2025;34(9):e70201.

Garashi HY, Steinke DT, Schafheutle EI. A systematic review of pharmacovigilance systems in developing countries using WHO indicators. Ther InnovRegul Sci. 2022;56(5):717-743.

Pandian S, Ragavan YV, Pandian AG, Kumaraguru AK, Subramanian KK. Enhancing public health with pharmacovigilance: tools, strategies, and impacts. Biomed Pharmacol J. 2025;18(2):1144-1151.

Suke SG, Kosta P, Negi H. Role of pharmacovigilance in India: an overview. Online J Public Health Inform. 2015;7(2).

Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med. 2016;16(5):481-485.

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259.

Ralph E. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1252.

Jiang H, Lin Y, Ren W, Fang Z, Liu Y, Tan X, et al. Adverse drug reactions and correlations with drug–drug interactions: a retrospective study. Front Pharmacol. 2022;13:923939.

Kommu S, Carter C, Whitfield P. Adverse drug reactions. StatPearls [Internet]. 2024.

Gangula D, Kshirsagar S, Dundigalla SK, Padi SS. Overview of adverse drug reactions: classification, reporting, prevention, and role of pharmacist. Int J Pharm Sci Rev Res. 2024;4:20-29.

Zhai J, Yan H, Zhang J, Yan H, Ma J, Zhang S. A comprehensive analysis of adverse drug reactions (2020–2023). Front Pharmacol. 2025;16:1628347.

Vonna A, Salahudeen MS, Peterson GM. Clinical outcomes of ADR-related hospital admissions in older adults with diabetes. Front Pharmacol. 2025;16:1729848.

Mwakawanga DL, Kilonzi M, Philipo EG, Martine A, Mbilinyi T, Kileo NF, et al. Pharmacovigilance and ADR reporting: healthcare providers’ experiences. Adv Pharmacol Pharm Sci. 2023;2023:5537592.

Bonneterre V, Bicout DJ, De Gaudemaris R. Application of pharmacovigilance methods in occupational health. Saf Health Work. 2012;3(2):92-100.

Siddique MI. Pharmacovigilance in the era of digital health: big data and AI. Asian J Pharm. 2025;19(1).

Kompa B, Hakim JB, Palepu A, Kompa KG, Smith M, Bain PA, et al. Artificial intelligence in pharmacovigilance: a scoping review. Drug Saf. 2022;45(5):477-491.

Alhejaily AM. Artificial intelligence in healthcare. Biomed Rep. 2024;22(1):11.

Al Kuwaiti A, Nazer K, Al-Reedy A, Al-Shehri S, Al-Muhanna A, Subbarayalu AV, et al. Role of artificial intelligence in healthcare. J Pers Med. 2023;13(6):951.

An Q, Rahman S, Zhou J, Kang JJ. Machine learning in healthcare industry: review. Sensors. 2023;23(9):4178.

Rahmani AM, Yousefpoor E, Yousefpoor MS, Mehmood Z, Haider A, Hosseinzadeh M, et al. Machine learning in medicine: review and challenges. Mathematics. 2021;9(22):2970.

Frommeyer TC, Gilbert MM, Fursmidt RM, Park Y, Khouzam JP, Brittain GV, et al. Reinforcement learning in healthcare. Healthcare. 2025;13(14):1752.

Patil HG, Khairnar VS. Impact of AI on pharmacovigilance: a systematic review. Int J Res Pharm Allied Sci. 2025;4(5):26-35.

Nagar A, Gobburu J, Chakravarty A. Artificial intelligence in pharmacovigilance: advancing drug safety monitoring. Ther Adv Drug Saf. 2025;16:20420986251361435.

Alam A, Shah SS, Rabbani SA, El-Tanani M. Role of artificial intelligence in pharmacy practice. BioMedInformatics. 2025;5(4):65.

Pilipiec P, Liwicki M, Bota A. Machine learning for pharmacovigilance: a systematic review. Pharmaceutics. 2022;14(2):266.

Published

2026-06-15

How to Cite

Sumit Dilare, Raj Baghel, Anil Kumar Yadav, & Muskan Tomar. (2026). AI-Driven Pharmacovigilance: Advances in Adverse Drug Reaction Detection and Signal Management - A Review. Asian Journal of Pharmaceutical Research and Development, 14(3), 139–146. https://doi.org/10.22270/ajprd.v14i3.1797